Clinical studies of drug-drug interactions: Design and interpretation

Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges

Volumn , Issue , 2010, Pages 625-649

  Greenblatt, David J ^a   Von Moltke, Lisa L ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956576179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0840-7_24     Document Type: Chapter

References (108)

1. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J and Chung M (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284-291.
2. Bachmann KA (2006) Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1-14.
3. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
4. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C and Jaillon P (1997) Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 61:619-627.
5. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H and Haefeli WE (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76:85-96.
6. Biaggioni I, Paul S, Puckett A and Arzubiaga C (1991) Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 258:588-593.
7. Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M, Aherne Z and Plume J (2004) Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol 57:162-169.
8. Brown HS, Galetin A, Hallifax D and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050.
9. Brown HS, Ito K, Galetin A and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
10. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E and Bertino JS, Jr. (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther 74:437-447.
11. Chan AW (1984) Effects of combined alcohol and benzodiazepine: a review. Drug Alcohol Depend 13:315-341.
12. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J and Alberts DS (2006) Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 15:2473-2476.
13. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U and Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517-528.
14. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML and Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141-152.
15. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
16. Crumb WJ, Jr., Wible B, Arnold DJ, Payne JP and Brown AM (1995) Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol 47:181-190.
17. Culm-Merdek KE, Von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH and Greenblatt DJ (2006) Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 79:243-254.
18. Culm-Merdek KE, Von Moltke LL, Harmatz JS and Greenblatt DJ (2005) Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br J Clin Pharmacol 60:486-493.
19. Cysneiros RM, Farkas D, Harmatz JS, Von Moltke LL and Greenblatt DJ (2007) Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther 82:54-62.
20. Davies SJ, Eayrs S, Pratt P and Lennard MS (2004) Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 57:464-472.
21. De Vane CL (2006) Antidepressant-drug interactions are potentially but rarely clinically significant. Neuropsychopharmacol 31:1594-1604.
22. Farkas D, Shader RI, Von Moltke LL and Greenblatt DJ (2008) Mechanisms and consequences of drug-drug interactions, in Preclinical Development Handbook (Gad SC ed) pp 879-917, Wiley-Interscience, Hoboken, NJ.
23. Friedman H, Greenblatt DJ, Burstein ES, Harmatz JS and Shader RI (1986) Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 22:639-642.
24. Fuhr U, Jetter A and Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81:270-283.
25. Galetin A, Burt H, Gibbons L and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
26. Galetin A, Hinton LK, Burt H, Obach RS and Houston JB (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693.
27. Galetin A and Houston JB (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220-1229.
28. Galetin A, Ito K, Hallifax D and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190.
29. Glintborg B, Andersen SE and Dalhoff K (2005) Drug-drug interactions among recently hospitalised patients - frequent but mostly clinically insignificant. Eur J Clin Pharmacol 61:675-681.
30. Granfors MT, Backman JT, Laitila J and Neuvonen PJ (2004a) Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 57:349-353.
31. Granfors MT, Backman JT, Neuvonen M, Ahonen J and Neuvonen PJ (2004b) Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 75:331-341.
32. Greenblatt DJ (2008) Preparation of scientific reports on pharmacokinetic drug interaction studies. J Clin Psychopharmacol 28:369-373.
33. Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS and Shader RI (1984) Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 310:1639-1643.
34. Greenblatt DJ, Harmatz JS, Friedman H, Locniskar A and Shader RI (1989) A large-sample study of diazepam pharmacokinetics. Ther Drug Monit 11:652-657.
35. Greenblatt DJ, He P, Von Moltke LL and Court MH (2008) The CYP3 family, in Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and Other Xenobiotics (Ioannides C ed) pp 354-383, Royal Society of Chemistry (Great Britain) RSC Pub; Springer, Cambridge; New York.
36. Greenblatt DJ, Shader RI, Weinberger DR, Allen MD and MacLaughlin DS (1978) Effect of a cocktail on diazepam absorption. Psychopharmacology (Berl) 57:199-203.
37. Greenblatt DJ and Von Moltke LL (2008) Drug-drug interactions: clinical perspectives, in Drug-Drug Interactions (Rodrigues AD ed) pp 643-664, Informa Healthcare, New York.
38. Greenblatt DJ, Von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE and Shader RI (1998a) Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 64:278-285.
39. Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL and Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136.
40. Greenblatt DJ, Von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP and Shader RI (2003) Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 43:414-422.
41. Greenblatt DJ, Von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol AL, Counihan M, Roth-Schechter B and Shader RI (1998b) Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 64:661-671.
42. Greenblatt DJ, Von Moltke LL, Harmatz JS and Shader RI (2002) Pharmacokinetics, pharmacodynamics, and drug disposition, in Neuropsychopharmacology the Fifth Generation of Progress (Davis KL and American College of Neuropsychopharmacology eds) pp 507-524, Lippincott Williams & Wilkins, Philadelphia.
43. Greenblatt DJ, Von Moltke LL, Harmatz JS and Shader RI (1999) Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 19(supp. 1):23S-35S.
44. Greenblatt DJ, Wright CE, Von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S and Shader RI (1998c) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247.
45. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
46. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y and Ang CY (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276-287.
47. Guzey C, Norstrom A and Spigset O (2002) Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 24:436-437.
48. Hemeryck A and Belpaire FM (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3:13-37.
49. Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
50. Honig PK, Woosley RL, Zamani K, Conner DP and Cantilena LR, Jr. (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238.
51. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE and Cantilena LR (1993a) Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 33:1201-1206.
52. Honig PK, Wortham DC, Zamani K and Cantilena LR (1994) Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin, and azithromycin on terfenadine steadystate pharmacokinetics and electrocardiographic parameters. Drug Invest 7:148-156.
53. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993b) Terfenadineketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269:1513-1518.
54. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H and Lesko LJ (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
55. Huang SM, Temple R, Throckmorton DC and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304.
56. Ito K, Brown HS and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
57. Ito K, Ogihara K, Kanamitsu S and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
58. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE and Brøsen K (1996a) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78.
59. Jeppesen U, Loft S, Poulsen HE and Brøsen K (1996b) A fluvoxamine-caffeine interaction study. Pharmacogenetics 6:213-222.
60. Jones TE (1997) The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 32:357-367.
61. Kanamitsu S, Ito K and Sugiyama Y (2000) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343.
62. Kaplan GB, Cotreau MM and Greenblatt DJ (1992a) Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo. J Pharm Pharmacol 44:700-703.
63. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G and Shader RI (1992b) Caffeineinduced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacol 6:145-153.
64. Kaplan GB, Greenblatt DJ, Kent MA and Cotreau-Bibbo MM (1993) Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. J Pharmacol Exp Ther 266:1563-1572.
65. Knox TA, Oleson L, Von Moltke LL, Kaufman RC, Wanke CA and Greenblatt DJ (2008) Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 49:358-368.
66. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA and Adson DE (2005) Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25:226-229.
67. Lacey LF, Keene ON, Pritchard JF and Bye A (1997) Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat 7:171-178.
68. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW and Frye RF (2002) Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72:718-728.
69. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
70. Lin JH (2000) Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 1:305-331.
71. Molden E, Garcia BH, Braathen P and Eggen AE (2005) Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 61:119-125.
72. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J and Cantilena LR, Jr. (1990) Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 264:2788-2790.
73. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
74. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
75. Ochs HR, Greenblatt DJ, Arendt RM, Hübbel W and Shader RI (1984) Pharmacokinetic noninteraction of triazolam and ethanol. J Clin Psychopharmacol 4:106-107.
76. Ohnhaus EE, Breckenridge AM and Park BK (1989) Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 36:39-46.
77. Ohno Y, Hisaka A and Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46:681-696.
78. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S and Ohashi K (2007) Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 47:871-876.
79. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M and Bialer M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56:471-476.
80. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M and Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90-98.
81. Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H and Levy RH (2007) Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab 8:810-814.
82. Rampe D, Wible B, Brown AM and Dage RC (1993) Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 44:1240-1245.
83. Reese MJ, Wurm RM, Muir KT, Generaux GT, John-Williams L and McConn DJ (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
84. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
85. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ and Norbeck DW (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42:3218-3224.
86. Smith DA, Abel SM, Hyland R and Jones BC (1998a) Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 28:1095-1128.
87. Smith G, Stubbins MJ, Harries LW and Wolf CR (1998b) Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129-1165.
88. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J and Wagner JA (2009) Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol 49:398-406.
89. Tanaka E, Kurata N and Yasuhara H (2003) How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 28:157-165.
90. Tsunoda SM, Velez RL, Von Moltke LL and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
91. Tucker GT, Houston JB and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 52:107-117.
92. Venkatakrishnan K, Von Moltke LL and Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111-180.
93. Venkatakrishnan K, Von Moltke LL and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
94. Venkatakrishnan K, Von Moltke LL, Obach RS and Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459.
95. Volak LP, Greenblatt DJ and Von Moltke LL (2007) In vitro approaches to anticipating clinical drug interactions, in Drug-drug interactions in pharmaceutical development (Li AP ed) pp 75-93, Wiley-interscience, Hoboken, N. J.
96. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS and Shader RI (1994a) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
97. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS and Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131.
98. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS and Shader RI (1994b) In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227.
99. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
100. Von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS and Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122.
101. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
102. Woosley RL, Chen Y, Freiman JP and Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc 269:1532-1536.
103. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I and Levy RH (2001) Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 70:415-424.
104. Yao C, Kunze KL, Trager WF, Kharasch ED and Levy RH (2003) Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos 31:565-571.
105. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F and Obach RS (2008) Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 65:680-692.
106. Zhou H, Tong Z and McLeod JF (2004) "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 44:120-134.
107. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.
108. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N and Zhou HH (2001) Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 70:455-461.